Can Gubra drive value creating partner programs?

Certainly.

Partner Programs

Gubra Partner Programs

Having engaged in a number of large partner programs, we have profound scientific capabilities and experience leading both target and drug discovery programs within Diabetes, Obesity, NASH and Gastrointestinal diseases.

Besides offering all necessary disciplines in-house (from molecular and in vivo pharmacology to peptide chemistry), we have professional project managers leading our partner programs. Projects are managed to meet deadlines and stay within budget while never compromising our high-quality outputs.

Get in touch

Get in touch if you are interested in discussing how to engage with Gubra on a partner program.

Trine Nygaard Hamann

Business Development
tnh@gubra.dk
+45 5124 9818

Get in touch

Contact us

Diabetes

There is a need for novel therapeutics with an added benefit to diabetes patients within diabetic complications, convenience, cardiovascular effects and risk of hypoglycemia. Reach out to discuss opportunities within diabetes.

Read more

NASH

There is an imminent need for approved medical treatment as well as biomarkers to ensure proper and efficient diagnosis. Find out more about our NASH program ready for partnering.

Read more

Obesity

Currently we are engaged in a partner program with Boehringer Ingelheim, however, we also have a number of other obesity partner programs ready for partnering.

Read more

Gastrointestinal diseases

Short Bowel Syndrome (SBS) is an orphan disease on the rise with significant unmet medical needs. We have a program focusing on GLP1/GLP2 co-agonist for Short Bowel Syndrome ready for partnering.

Read more

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

info@gubra.dk
+45 3152 ­2650